Search - tctmd.com

Displaying 561 - 580 of 891

Sort: Relevancy | Date

Presentation TCT 2016

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx, Deepak L. Bhatt

November 01, 2016

Presentation TCT 2016

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx, Roxana Mehran

November 01, 2016

Presentation TCT 2016

Which Device and Technique for This Patient?

Presenter: Ganesh Manoharan, Hendrik Treede, Tamim Nazif, Torsten P. Vahl

November 01, 2016

Presentation TCT 2016

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx

November 01, 2016

Presentation TCT 2016

Balloon Angioplasty Vs Bare Metal Vs Stents Covered Stents: How Do You Make the Decision?

Presenter: John D. Carroll, Thomas J Forbes, Elchanan Bruckheimer

November 01, 2016

Presentation TCT 2016

Very Long Term Outcomes after FFR-Based Decision-Making

Presenter: Nick Curzen, Nils Johnson, Frederik M. Zimmermann

November 01, 2016

Presentation TCT 2016

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx, C. Michael Gibson

November 01, 2016

Presentation TCT 2016

Acute Anticoagulation Management and Bleeding Avoidance Strategies in the Chronic AF Patient Who Requires PCI

Presenter: David P. Faxon, C. Michael Gibson, Deepak L. Bhatt

November 01, 2016

Presentation TCT 2016

When and Which Antiplatelet Agent Should be Dropped When Using Oral Anticoagulant Therapy?

Presenter: David P. Faxon, C. Michael Gibson, Roxana Mehran

November 01, 2016

Presentation TCT 2016

Dosing Considerations of Oral Anticoagulant Therapy in the ACS and PCI Patient: Optimizing Efficacy While Minimizing Bleeding

Presenter: David P. Faxon, C. Michael Gibson

November 01, 2016

Presentation TCT 2016

Industry Perspectives: Balancing Innovation and Robust Clinical Evidence Generation With Declining DES Use and Reimbursement

Presenter: Michael C. John, Gregg W. Stone, Jason R. Weidman

November 01, 2016

Presentation TCT 2016

General Overview and Highlights of the North American Consensus Document on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI

Presenter: David P. Faxon, C. Michael Gibson, Dominick J. Angiolillo

November 01, 2016

Presentation TCT 2016

European Guidelines on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI

Presenter: David P. Faxon, C. Michael Gibson, Davide Capodanno

November 01, 2016

Presentation TCT 2016

What Is Known (and What Is Not) About Discontinuing Aspirin or Clopidogrel in Patients on Chronic Oral Anticoagulants Plus DAPT

Presenter: David P. Faxon, C. Michael Gibson, Freek W.A. Verheugt

November 01, 2016

Presentation TCT 2016

The Big Picture: Incremental Bleeding Risks in Patients Requiring Chronic Oral Anticoagulants Plus DAPT

Presenter: David P. Faxon, C. Michael Gibson, Christopher B. Granger

November 01, 2016

Presentation TCT 2016

Case Resolution: What Was Done

Presenter: John A. Bittl, David J. Maron, Kishore J. Harjai

November 01, 2016

Presentation TCT 2016

My Top Predictions for the Next Decade of Vulnerable Plaque Research: Insights From a Soothsayer

Presenter: Gregg W. Stone, Ron Waksman, John A. Ambrose

November 01, 2016

Presentation TCT 2016

When Equipoise Exists: Is Unbiased, Informed Consent Possible?

Presenter: John A. Bittl, David J. Maron, John A. Spertus

November 01, 2016

Presentation TCT 2016

The Case for Multivessel PCI

Presenter: John A. Bittl, David J. Maron, Sripal Bangalore

November 01, 2016

Presentation TCT 2016

Case #3 - Introduction: Professional Diver With Decompression Illness

Presenter: John D. Carroll, David E. Thaler, Michael J. Mullen

November 01, 2016

Advertisement

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

Which Device and Technique for This Patient?

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

Balloon Angioplasty Vs Bare Metal Vs Stents Covered Stents: How Do You Make the Decision?

Very Long Term Outcomes after FFR-Based Decision-Making

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

Acute Anticoagulation Management and Bleeding Avoidance Strategies in the Chronic AF Patient Who Requires PCI

When and Which Antiplatelet Agent Should be Dropped When Using Oral Anticoagulant Therapy?

Dosing Considerations of Oral Anticoagulant Therapy in the ACS and PCI Patient: Optimizing Efficacy While Minimizing Bleeding

Industry Perspectives: Balancing Innovation and Robust Clinical Evidence Generation With Declining DES Use and Reimbursement

General Overview and Highlights of the North American Consensus Document on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI

European Guidelines on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI

What Is Known (and What Is Not) About Discontinuing Aspirin or Clopidogrel in Patients on Chronic Oral Anticoagulants Plus DAPT

The Big Picture: Incremental Bleeding Risks in Patients Requiring Chronic Oral Anticoagulants Plus DAPT

Case Resolution: What Was Done

My Top Predictions for the Next Decade of Vulnerable Plaque Research: Insights From a Soothsayer

When Equipoise Exists: Is Unbiased, Informed Consent Possible?

The Case for Multivessel PCI

Case #3 - Introduction: Professional Diver With Decompression Illness

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content